Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases
复制标题

DOI:
10.1002/hep.31065
复制
发表时间:
2020-05-12
期刊:
影响因子:
13.5
通讯作者:
Czaja, Albert J.
Czaja, Albert J.
中科院分区:
医学1区
文献类型:
--
作者:
Mack, Cara L.;Adams, David;Czaja, Albert J.

文献摘要

被引文献

相似文献

缩写:AASLD,美国肝病研究协会; AIH,自身免疫性肝炎; ALF,急性肝功能衰竭; ALT,丙氨酸转氨酶; AMA,抗线粒体抗体; ANA,抗核抗体;抗α-肌动蛋白,α-肌动蛋白抗体;抗-HBc,乙型肝炎核心抗原抗体;抗 LC1,肝细胞质 1 型抗体;抗-LKM1,LKM1 抗体;抗PD-1,PD-1抗体;抗 SLA,SLA 抗体; ARFI,声辐射力脉冲成像; ASC,自身免疫性硬化性胆管炎; AST,天冬氨酸转氨酶; AZA,硫唑嘌呤; Breg,B 调节细胞; CD,分化簇; CI,置信区间; CsA、环孢素; CTL,细胞毒性T淋巴细胞; CTLA-4,细胞毒性T淋巴细胞抗原4; GGT,γ-谷氨酰转移酶; GRADE,建议评估、制定和评价的分级; HAV,甲型肝炎病毒; HBsAg,乙型肝炎表面抗原; HBV,乙型肝炎病毒; HCC,肝细胞癌; HLA,人类白细胞抗原; IAIHG,国际自身免疫性肝炎小组; IBD,炎症性肠病; IgG、免疫球蛋白G; IL,白细胞介素; INR,国际标准化比率; iTreg,诱导性 T 调节细胞; LKM1,肝肾微粒体1型; LT,肝移植; MAIT,粘膜不变T; MMF,吗替麦考酚酯; 6-MP,6-巯基嘌呤; MRE,磁共振弹性成像; NAFLD,非酒精性脂肪肝; NASH,非酒精性脂肪性肝炎; NK,自然杀手;或,优势比; pANCA,核周抗中性粒细胞胞浆抗体; PBC,原发性胆汁性胆管炎; PD-1,程序性死亡蛋白-1; PSC,原发性硬化性胆管炎; SLA,可溶性肝抗原; SMA、平滑肌
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIH, autoimmune hepatitis; ALF, acute liver failure; ALT, alanine aminotransferase; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; anti-α-actinin, antibody to alpha-actinin; anti-HBc, antibodies to hepatitis B core antigen; anti-LC1, antibodies to liver cytosol type 1; anti-LKM1, antibodies to LKM1; anti-PD-1, antibody to PD-1; anti-SLA, antibodies to SLA; ARFI, acoustic radiation force impulse imaging; ASC, autoimmune sclerosing cholangitis; AST, aspartate aminotransferase; AZA, azathioprine; Breg, B regulatory cell; CD, cluster of differentiation; CI, confidence interval; CsA, cyclosporine; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T lymphocyte antigen-4; GGT, gamma-glutamyltransferase; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HLA, human leukocyte antigen; IAIHG, International Autoimmune Hepatitis Group; IBD, inflammatory bowel disease; IgG, immunoglobulin G; IL, interleukin; INR, international normalized ratio; iTreg, inducible T regulatory cell; LKM1, liver kidney microsome type 1; LT, liver transplantation; MAIT, mucosal invariant T; MMF, mycophenolate mofetil; 6-MP, 6-mercaptopurine; MRE, magnetic resonance elastography; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NK, natural killer; OR, odds ratio; pANCA, perinuclear antineutrophil cytoplasmic antibody; PBC, primary biliary cholangitis; PD-1, programmed death protein-1; PSC, primary sclerosing cholangitis; SLA, soluble liver antigen; SMA, smooth muscle